News Briefs: Device Tax Repeal Momentum; J&J Settles Hip Suit; Mobile Medical Apps Bill

Device tax repeal momentum. Johnson & Johnson/DePuy has settled a lawsuit from a California plaintiff related to injuries from the ASR hip implant. Rep. Marsha Blackburn is working on legislation to clarify FDA’s authority over mobile health apps. Zimmer will market Frontier’s Lateral Locking Cage. More news.

A bipartisan group of Senators are discussing a new vehicle to break through the continuing resolution and debt ceiling logjams in Congress, with device tax repeal a core component, according press reports. Spear-headed by Sens. Susan Collins, R-Maine, and Chuck Schumer, D-N.Y., the draft plan would include a long-term extension of government funding at sequestration levels; a debt limit increase for more than a year; a repeal of medical device tax, and changes to the Independent Payment Advisory Board among other elements, Politico reported last Thursday.

Meanwhile, The Hill newspaper stated Oct. 10 that the overall plan came from Senate Republican Leader Mitch McConnell of Kentucky, and that Sen. John McCain, R-Ariz., is a supporter of making device tax repeal a major part of the deal. Other backers of the plan include Democratic Sens. Joe Manchin ,W.Va., and Dick Durbin, Ill.; as well as Tennessee Republicans Bob Corker and Lamar Alexander, Politico wrote. But it is still unclear whether the Senators would accept the use of a pension stabilization provision, part of a transportation authorization bill, as a “pay-for” to replace device tax revenues. That pay-for is being advanced in the House by Reps. Charlie Dent, R-Pa., and Ron Kind, D-Wis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.